Skip to main content
SpringerLink
Log in

How to Use Anti-influenza Drugs: Laninamivir Octanoate

  • Chapter
  • First Online:
Influenza

  • 530 Accesses

Abstract

A neuraminidase inhibitor, laninamivir octanoate (Inavir®; Daiichi Sankyo, Tokyo, Japan) is an inhaled drug with unique characteristics. The inhaled laninamivir octanoate is converted into its active form, laninamivir, in the lungs where a high concentration continues for a long period of time. The concentration of laninamivir exceeds the level necessary for virus replication inhibition for at least 5 days, thus treatment for influenza can be completed with only a single administration through inhalation.

Clinical trials have shown comparable efficacy for laninamivir octanoate and oseltamivir, but an advantage of laninamivir octanoate is that it has sufficient antiviral effect against A(H1N1) with NA/H275Y mutated oseltamivir resistant virus. Clinical observation showing a consistent duration of fever after inhalation and continued susceptibility of epidemic viruses to laninamivir over several Japanese influenza season supports the continued clinical effectiveness of laninamivir octanoate. No resistant virus has been clinically observed for laninamivir octanoate even though it has been widely used. The prophylactic efficacy of laninamivir octanoate has been shown both in animal models and post-exposure prophylaxis in household contacts.

A major clinical benefit of this drug is that the single administration provides great convenience for both the patient and doctor, which leads to improved compliance. No emergence or transmission of resistant virus had been observed, resulting in freedom from anxiety about resistant virus. Further, this drug shows great promise for the treatment of influenza in future pandemics because of its effectiveness against all types of influenza viruses investigated in preclinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. WHO. Transmission dynamics and impact of pandemic influenza A(H1N1) 2009 virus. Wkly Epidemiol Rec. 2009;46:481–4. http://www.who.int/wer/2009/wer8446.pdf.

    Google Scholar 

  2. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68:895–902.

    Article  Google Scholar 

  3. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis. 2006;43:439–44.

    Article  CAS  Google Scholar 

  4. Kawai N, Ikematsu H, Iwaki N, Maeda T, Kawashima T, Hirotsu N, et al. Comparison of the effectiveness of zanamivir and oseltamivir against influenza A/H1N1, A/H3N2, and B. Clin Infect Dis. 2009;48:996–7.

    Article  Google Scholar 

  5. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S, Ishikawa Y, Yamaguchi H, et al. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons. J Infect Chemother. 2018;24:718–24.

    Article  CAS  Google Scholar 

  6. Koyama K, Takahashi M, Oitate M, Nakai N, Takakusa H, Miura S, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009;53:4845–51.

    Article  CAS  Google Scholar 

  7. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, Yamashita M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010;6:e1000786.

    Article  Google Scholar 

  8. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53:186–92.

    Article  CAS  Google Scholar 

  9. Itoh Y, Shinya K, Kiso M, Sakoda Y, Hatta M, Muramoto Y, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:1021–5.

    Article  CAS  Google Scholar 

  10. Kubo S, Kakuta M, Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses. Jpn J Antibiot. 2010;63:337–46.

    CAS  PubMed  Google Scholar 

  11. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol. 2010;50:1319–20.

    Article  CAS  Google Scholar 

  12. Kubo S, Tokumitsu A, Tomozawa T, Kakuta M, Yamashita M. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals. J Infect Chemother. 2012;18:69–74.

    Article  CAS  Google Scholar 

  13. Yamashita M, Hirai T, Kubota K, Kubo S. Unique characteristics of long acting neuraminidase inhibitor laninamivir octanoate (CS-8958) that explains its long-lasting activity. Influenza Other Respir Viruses. 2010;5(Suppl 1):93–5.

    Google Scholar 

  14. Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother. 2010;54:1256–64.

    Article  CAS  Google Scholar 

  15. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013;501:551–5.

    Article  CAS  Google Scholar 

  16. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51:1167–75.

    Article  CAS  Google Scholar 

  17. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575–82.

    Article  CAS  Google Scholar 

  18. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S, Ishikawa Y, Yamaguchi H, Shiosakai K. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons. J Infect Chemother. 2018;24:718–24.

    Article  CAS  Google Scholar 

  19. Kashiwagi S, Yoshida S, Yamaguchi H, Niwa S, Mitsui N, Tanigawa M, et al. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance. Int J Antimicrob Agents. 2012;40:381–8.

    Article  CAS  Google Scholar 

  20. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eur Secur. 2008;13:1–2.

    Google Scholar 

  21. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis. 2009;49:1828–35.

    Article  CAS  Google Scholar 

  22. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect. 2009;59:207–12.

    Article  Google Scholar 

  23. https://www.niid.go.jp/niid/en/influ-resist-e.html.

  24. Ikematsu H, Kawai N, Chong Y, Bando T, Iwaki N, Kashiwagi S. In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2017–18 season: comparison with the 2010–11 to 2016–17 seasons. J Infect Chemother. 2019;25:649–52.

    Article  CAS  Google Scholar 

  25. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003–32.

    Article  CAS  Google Scholar 

  26. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60:1–24.

    PubMed  Google Scholar 

  27. Kashiwagi S, Watanabe A, Ikematsu H, Uemori M, Awamura S. Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza. Clin Infect Dis. 2016;63:330–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ricerca Clinica Co., Influenza Study Group, Japan Physicians Association, Fukuoka, Japan

    Hideyuki Ikematsu

Authors
  1. Hideyuki Ikematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideyuki Ikematsu .

Editor information

Editors and Affiliations

  1. Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

    Jiro Fujita

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ikematsu, H. (2021). How to Use Anti-influenza Drugs: Laninamivir Octanoate. In: Fujita, J. (eds) Influenza. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-15-9109-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-9109-9_16

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-9108-2

  • Online ISBN: 978-981-15-9109-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation